- Home
- MTAL vs PHVS Comparison
MTAL vs PHVS Comparison
Compare MTAL & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- PHVS
- Stock Information
- Founded
- MTAL 2021
- PHVS 2015
- Country
- MTAL Jersey
- PHVS Switzerland
- Employees
- MTAL N/A
- PHVS N/A
- Industry
- MTAL Blank Checks
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- MTAL Finance
- PHVS Health Care
- Exchange
- MTAL Nasdaq
- PHVS Nasdaq
- Market Cap
- MTAL 997.3M
- PHVS 980.3M
- IPO Year
- MTAL 2021
- PHVS 2021
- Fundamental
- Price
- MTAL $12.05
- PHVS $22.32
- Analyst Decision
- MTAL Hold
- PHVS Buy
- Analyst Count
- MTAL 4
- PHVS 6
- Target Price
- MTAL $12.08
- PHVS $37.17
- AVG Volume (30 Days)
- MTAL 757.6K
- PHVS 30.0K
- Earning Date
- MTAL 08-09-2025
- PHVS 08-13-2025
- Dividend Yield
- MTAL N/A
- PHVS N/A
- EPS Growth
- MTAL N/A
- PHVS N/A
- EPS
- MTAL N/A
- PHVS N/A
- Revenue
- MTAL $340,736,000.00
- PHVS N/A
- Revenue This Year
- MTAL $18.41
- PHVS N/A
- Revenue Next Year
- MTAL $23.55
- PHVS N/A
- P/E Ratio
- MTAL N/A
- PHVS N/A
- Revenue Growth
- MTAL 114.30
- PHVS N/A
- 52 Week Low
- MTAL $7.69
- PHVS $11.51
- 52 Week High
- MTAL $14.93
- PHVS $25.50
- Technical
- Relative Strength Index (RSI)
- MTAL 60.65
- PHVS 73.31
- Support Level
- MTAL $11.94
- PHVS $17.63
- Resistance Level
- MTAL $12.09
- PHVS $19.00
- Average True Range (ATR)
- MTAL 0.09
- PHVS 1.20
- MACD
- MTAL -0.07
- PHVS 0.35
- Stochastic Oscillator
- MTAL 50.00
- PHVS 92.15
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.